

**Adult CIRB - Early Phase Emphasis Meeting Agenda**

**April 16, 2024**

---

**I Amendment**

**9846**, Patient-Derived Models Tissue Procurement Protocol For The National Cancer Institute (NCI) (Version Date 03/05/24)

---

**II Continuing Review**

**10005**, A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma (Version Date 10/04/23)

---

**III Continuing Review**

**10301**, A Phase I and Randomized Phase II Trial of Radium-223 dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC) (Version Date 02/13/24)

---

**IV Continuing Review**

**9938**, Phase I clinical trial of M6620 (VX-970, berzosertib) in combination with the topoisomerase I inhibitor irinotecan in patients with advanced solid tumors (Version Date 08/29/22)

---

**V Continuing Review**

**10387**, Pilot Trial of Nivolumab plus Cabozantinib for Advanced Solid Tumors in Patients with HIV Infection (Version Date 08/24/23)

---

**VI Continuing Review**

**10100**, A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination with Atezolizumab Compared to Atezolizumab Alone in Subjects with Locally Advanced or Metastatic Transitional Cell



## Urothelial Cancer Where Cisplatin-Based Treatment is Not an Option (Version Date 10/05/23)

---